You are here: Industry Insights > Biocon

News List

Biocon enters Dow Jones Sustainability Emerging Markets Index expresspharma
December 02, 2021
The company made a formal submission for Corporate Sustainability Assessment for its listing on DJSI for the first time this year and made it to the DJSI EM Index with a total Sustainability Score of 45 as against an industry average of 18, achieving...
Biocon Biologics and Adagio Therapeutics to develop antibody treatment for COVID-19 expresspharma
July 28, 2021
Biocon Biologics to manufacture and commercialise a broadly neutralising antibody for India and select emerging markets.
Biocon Q1FY22 revenue at Rs 1,808 crores, up six per cent expresspharma
July 23, 2021
Biosimilars up 10 per cent at Rs 758 crores and research services up 41 per cent at Rs 595 crores.
Dr Kiran Mazumdar Shaw donates Rs 5 crores to Ignite Life Science Foundation expresspharma
June 09, 2021
Dr Kiran Mazumdar Shaw, Biocon founder and Executive Chairperson announced a contribution of Rs 5 crores to Ignite Life Science Foundation, to trigger funding for research at Indian scientific institutions.
Biocon Pharma gets GMP compliance certificate from MHRA, UK expresspharma
April 13, 2021
Biocon Pharma, a wholly-owned subsidiary of Biocon, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines & Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility ...
Biocon Pharma joins hands with Libbs Farmaceutica to launch generic medicines in Brazil expresspharma
March 29, 2021
Biocon Pharma will be responsible for drug development and manufacturing of the medicines, while Libbs will import, distribute and market, subject to approvals from ANVISA.
Mylan-UpJohn merger as Viatris provides opportunity to focus on biosimilar launch and uptake expresspharma
March 17, 2021
Following the news that the European Medicines Agency (EMA) has approved Kixelle, Biocon/Mylan’s biosimilar of Novo Nordisk’s Novolog/NovoRapid (insulin aspart).
Biocon Biologics partners with IDF to improve access to insulins expresspharma
February 18, 2021
Biocon Biologics, a subsidiary of Biocon, has announced a partnership with the International Diabetes Federation (IDF) to promote and support IDF’s Core Mission initiative and activities.
Biocon Biologics and Viatris get EC Approval for Kixelle, biosimilar insulin Aspart expresspharma
February 18, 2021
Kixelle, a fast-acting insulin analog indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above, has been approved as a 100 units/ml solution for injection in vial and pre-filled pen presentations.
Biocon launches Tacrolimus capsules in US expresspharma
December 29, 2020
It is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ.

Previous page 1 2 3 4 5 6 Next page